世界のアンチセンス・RNAi治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Antisense and RNAi Therapeutics Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z0412 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品、ヘルスケア

• 販売価格（消費税別）

Single User	￥553,800 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥830,700 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,107,600 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、アンチセンス・RNAi治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（RNA干渉、アンチセンスRNA）、用途別市場規模（病院、クリニック）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・アンチセンス・RNAi治療の市場動向 ・企業の競争状況、市場シェア ・アンチセンス・RNAi治療の種類別市場規模（RNA干渉、アンチセンスRNA） ・アンチセンス・RNAi治療の用途別市場規模（病院、クリニック） ・アンチセンス・RNAi治療の北米市場規模2016-2027（アメリカ、カナダ） ・アンチセンス・RNAi治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・アンチセンス・RNAi治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・アンチセンス・RNAi治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・アンチセンス・RNAi治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Tekmira Pharmaceuticals、Arbutus Biopharma、Alnylam Pharmaceuticals、Antisense Therapeutics、Silence Therapeutics、Isis Pharmaceuticals、Sirnaomics、Santaris、Roche） ・結論

Market Analysis and Insights: Global Antisense and RNAi Therapeutics Market
The global Antisense and RNAi Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Antisense and RNAi Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Antisense and RNAi Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Antisense and RNAi Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Antisense and RNAi Therapeutics market.

Global Antisense and RNAi Therapeutics Scope and Market Size
Antisense and RNAi Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Antisense and RNAi Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
RNA Interference
Antisense RNA

Segment by Application
Hospital
Clinic

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Tekmira Pharmaceuticals
Arbutus Biopharma
Alnylam Pharmaceuticals
Antisense Therapeutics
Silence Therapeutics
Isis Pharmaceuticals
Sirnaomics
Santaris
Roche

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antisense and RNAi Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 RNA Interference
1.2.3 Antisense RNA
1.3 Market by Application
1.3.1 Global Antisense and RNAi Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Antisense and RNAi Therapeutics Market Perspective (2016-2027)
2.2 Antisense and RNAi Therapeutics Growth Trends by Regions
2.2.1 Antisense and RNAi Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Antisense and RNAi Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Antisense and RNAi Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Antisense and RNAi Therapeutics Industry Dynamic
2.3.1 Antisense and RNAi Therapeutics Market Trends
2.3.2 Antisense and RNAi Therapeutics Market Drivers
2.3.3 Antisense and RNAi Therapeutics Market Challenges
2.3.4 Antisense and RNAi Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Antisense and RNAi Therapeutics Players by Revenue
3.1.1 Global Top Antisense and RNAi Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Antisense and RNAi Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Antisense and RNAi Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Antisense and RNAi Therapeutics Revenue
3.4 Global Antisense and RNAi Therapeutics Market Concentration Ratio
3.4.1 Global Antisense and RNAi Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antisense and RNAi Therapeutics Revenue in 2020
3.5 Antisense and RNAi Therapeutics Key Players Head office and Area Served
3.6 Key Players Antisense and RNAi Therapeutics Product Solution and Service
3.7 Date of Enter into Antisense and RNAi Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Antisense and RNAi Therapeutics Breakdown Data by Type
4.1 Global Antisense and RNAi Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Antisense and RNAi Therapeutics Forecasted Market Size by Type (2022-2027)

5 Antisense and RNAi Therapeutics Breakdown Data by Application
5.1 Global Antisense and RNAi Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Antisense and RNAi Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Antisense and RNAi Therapeutics Market Size (2016-2027)
6.2 North America Antisense and RNAi Therapeutics Market Size by Type
6.2.1 North America Antisense and RNAi Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Antisense and RNAi Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Antisense and RNAi Therapeutics Market Size by Type (2016-2027)
6.3 North America Antisense and RNAi Therapeutics Market Size by Application
6.3.1 North America Antisense and RNAi Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Antisense and RNAi Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Antisense and RNAi Therapeutics Market Size by Application (2016-2027)
6.4 North America Antisense and RNAi Therapeutics Market Size by Country
6.4.1 North America Antisense and RNAi Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Antisense and RNAi Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Antisense and RNAi Therapeutics Market Size (2016-2027)
7.2 Europe Antisense and RNAi Therapeutics Market Size by Type
7.2.1 Europe Antisense and RNAi Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Antisense and RNAi Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Antisense and RNAi Therapeutics Market Size by Type (2016-2027)
7.3 Europe Antisense and RNAi Therapeutics Market Size by Application
7.3.1 Europe Antisense and RNAi Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Antisense and RNAi Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Antisense and RNAi Therapeutics Market Size by Application (2016-2027)
7.4 Europe Antisense and RNAi Therapeutics Market Size by Country
7.4.1 Europe Antisense and RNAi Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Antisense and RNAi Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Antisense and RNAi Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Antisense and RNAi Therapeutics Market Size by Type
8.2.1 Asia-Pacific Antisense and RNAi Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Antisense and RNAi Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Antisense and RNAi Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Antisense and RNAi Therapeutics Market Size by Application
8.3.1 Asia-Pacific Antisense and RNAi Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Antisense and RNAi Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Antisense and RNAi Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Antisense and RNAi Therapeutics Market Size by Region
8.4.1 Asia-Pacific Antisense and RNAi Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Antisense and RNAi Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Antisense and RNAi Therapeutics Market Size (2016-2027)
9.2 Latin America Antisense and RNAi Therapeutics Market Size by Type
9.2.1 Latin America Antisense and RNAi Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Antisense and RNAi Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Antisense and RNAi Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Antisense and RNAi Therapeutics Market Size by Application
9.3.1 Latin America Antisense and RNAi Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Antisense and RNAi Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Antisense and RNAi Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Antisense and RNAi Therapeutics Market Size by Country
9.4.1 Latin America Antisense and RNAi Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Antisense and RNAi Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Antisense and RNAi Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Antisense and RNAi Therapeutics Market Size by Type
10.2.1 Middle East & Africa Antisense and RNAi Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Antisense and RNAi Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Antisense and RNAi Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Antisense and RNAi Therapeutics Market Size by Application
10.3.1 Middle East & Africa Antisense and RNAi Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Antisense and RNAi Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Antisense and RNAi Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Antisense and RNAi Therapeutics Market Size by Country
10.4.1 Middle East & Africa Antisense and RNAi Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Antisense and RNAi Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Tekmira Pharmaceuticals
11.1.1 Tekmira Pharmaceuticals Company Details
11.1.2 Tekmira Pharmaceuticals Business Overview
11.1.3 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Introduction
11.1.4 Tekmira Pharmaceuticals Revenue in Antisense and RNAi Therapeutics Business (2016-2021)
11.1.5 Tekmira Pharmaceuticals Recent Development
11.2 Arbutus Biopharma
11.2.1 Arbutus Biopharma Company Details
11.2.2 Arbutus Biopharma Business Overview
11.2.3 Arbutus Biopharma Antisense and RNAi Therapeutics Introduction
11.2.4 Arbutus Biopharma Revenue in Antisense and RNAi Therapeutics Business (2016-2021)
11.2.5 Arbutus Biopharma Recent Development
11.3 Alnylam Pharmaceuticals
11.3.1 Alnylam Pharmaceuticals Company Details
11.3.2 Alnylam Pharmaceuticals Business Overview
11.3.3 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Introduction
11.3.4 Alnylam Pharmaceuticals Revenue in Antisense and RNAi Therapeutics Business (2016-2021)
11.3.5 Alnylam Pharmaceuticals Recent Development
11.4 Antisense Therapeutics
11.4.1 Antisense Therapeutics Company Details
11.4.2 Antisense Therapeutics Business Overview
11.4.3 Antisense Therapeutics Antisense and RNAi Therapeutics Introduction
11.4.4 Antisense Therapeutics Revenue in Antisense and RNAi Therapeutics Business (2016-2021)
11.4.5 Antisense Therapeutics Recent Development
11.5 Silence Therapeutics
11.5.1 Silence Therapeutics Company Details
11.5.2 Silence Therapeutics Business Overview
11.5.3 Silence Therapeutics Antisense and RNAi Therapeutics Introduction
11.5.4 Silence Therapeutics Revenue in Antisense and RNAi Therapeutics Business (2016-2021)
11.5.5 Silence Therapeutics Recent Development
11.6 Isis Pharmaceuticals
11.6.1 Isis Pharmaceuticals Company Details
11.6.2 Isis Pharmaceuticals Business Overview
11.6.3 Isis Pharmaceuticals Antisense and RNAi Therapeutics Introduction
11.6.4 Isis Pharmaceuticals Revenue in Antisense and RNAi Therapeutics Business (2016-2021)
11.6.5 Isis Pharmaceuticals Recent Development
11.7 Sirnaomics
11.7.1 Sirnaomics Company Details
11.7.2 Sirnaomics Business Overview
11.7.3 Sirnaomics Antisense and RNAi Therapeutics Introduction
11.7.4 Sirnaomics Revenue in Antisense and RNAi Therapeutics Business (2016-2021)
11.7.5 Sirnaomics Recent Development
11.8 Santaris
11.8.1 Santaris Company Details
11.8.2 Santaris Business Overview
11.8.3 Santaris Antisense and RNAi Therapeutics Introduction
11.8.4 Santaris Revenue in Antisense and RNAi Therapeutics Business (2016-2021)
11.8.5 Santaris Recent Development
11.9 Roche
11.9.1 Roche Company Details
11.9.2 Roche Business Overview
11.9.3 Roche Antisense and RNAi Therapeutics Introduction
11.9.4 Roche Revenue in Antisense and RNAi Therapeutics Business (2016-2021)
11.9.5 Roche Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Antisense and RNAi Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of RNA Interference
Table 3. Key Players of Antisense RNA
Table 4. Global Antisense and RNAi Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Antisense and RNAi Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Antisense and RNAi Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Antisense and RNAi Therapeutics Market Share by Regions (2016-2021)
Table 8. Global Antisense and RNAi Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Antisense and RNAi Therapeutics Market Share by Regions (2022-2027)
Table 10. Antisense and RNAi Therapeutics Market Trends
Table 11. Antisense and RNAi Therapeutics Market Drivers
Table 12. Antisense and RNAi Therapeutics Market Challenges
Table 13. Antisense and RNAi Therapeutics Market Restraints
Table 14. Global Antisense and RNAi Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Antisense and RNAi Therapeutics Market Share by Players (2016-2021)
Table 16. Global Top Antisense and RNAi Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antisense and RNAi Therapeutics as of 2020)
Table 17. Ranking of Global Top Antisense and RNAi Therapeutics Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Antisense and RNAi Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Antisense and RNAi Therapeutics Product Solution and Service
Table 21. Date of Enter into Antisense and RNAi Therapeutics Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Antisense and RNAi Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Antisense and RNAi Therapeutics Revenue Market Share by Type (2016-2021)
Table 25. Global Antisense and RNAi Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Antisense and RNAi Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Antisense and RNAi Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Antisense and RNAi Therapeutics Revenue Market Share by Application (2016-2021)
Table 29. Global Antisense and RNAi Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Antisense and RNAi Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Antisense and RNAi Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Antisense and RNAi Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Antisense and RNAi Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Antisense and RNAi Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Antisense and RNAi Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Antisense and RNAi Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Antisense and RNAi Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Antisense and RNAi Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Antisense and RNAi Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Antisense and RNAi Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Antisense and RNAi Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Antisense and RNAi Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Antisense and RNAi Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Antisense and RNAi Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Antisense and RNAi Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Antisense and RNAi Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Antisense and RNAi Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Antisense and RNAi Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Antisense and RNAi Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Antisense and RNAi Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Antisense and RNAi Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Antisense and RNAi Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Antisense and RNAi Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Antisense and RNAi Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Antisense and RNAi Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Antisense and RNAi Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Antisense and RNAi Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Antisense and RNAi Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Antisense and RNAi Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Antisense and RNAi Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 61. Tekmira Pharmaceuticals Company Details
Table 62. Tekmira Pharmaceuticals Business Overview
Table 63. Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Product
Table 64. Tekmira Pharmaceuticals Revenue in Antisense and RNAi Therapeutics Business (2016-2021) & (US$ Million)
Table 65. Tekmira Pharmaceuticals Recent Development
Table 66. Arbutus Biopharma Company Details
Table 67. Arbutus Biopharma Business Overview
Table 68. Arbutus Biopharma Antisense and RNAi Therapeutics Product
Table 69. Arbutus Biopharma Revenue in Antisense and RNAi Therapeutics Business (2016-2021) & (US$ Million)
Table 70. Arbutus Biopharma Recent Development
Table 71. Alnylam Pharmaceuticals Company Details
Table 72. Alnylam Pharmaceuticals Business Overview
Table 73. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Product
Table 74. Alnylam Pharmaceuticals Revenue in Antisense and RNAi Therapeutics Business (2016-2021) & (US$ Million)
Table 75. Alnylam Pharmaceuticals Recent Development
Table 76. Antisense Therapeutics Company Details
Table 77. Antisense Therapeutics Business Overview
Table 78. Antisense Therapeutics Antisense and RNAi Therapeutics Product
Table 79. Antisense Therapeutics Revenue in Antisense and RNAi Therapeutics Business (2016-2021) & (US$ Million)
Table 80. Antisense Therapeutics Recent Development
Table 81. Silence Therapeutics Company Details
Table 82. Silence Therapeutics Business Overview
Table 83. Silence Therapeutics Antisense and RNAi Therapeutics Product
Table 84. Silence Therapeutics Revenue in Antisense and RNAi Therapeutics Business (2016-2021) & (US$ Million)
Table 85. Silence Therapeutics Recent Development
Table 86. Isis Pharmaceuticals Company Details
Table 87. Isis Pharmaceuticals Business Overview
Table 88. Isis Pharmaceuticals Antisense and RNAi Therapeutics Product
Table 89. Isis Pharmaceuticals Revenue in Antisense and RNAi Therapeutics Business (2016-2021) & (US$ Million)
Table 90. Isis Pharmaceuticals Recent Development
Table 91. Sirnaomics Company Details
Table 92. Sirnaomics Business Overview
Table 93. Sirnaomics Antisense and RNAi Therapeutics Product
Table 94. Sirnaomics Revenue in Antisense and RNAi Therapeutics Business (2016-2021) & (US$ Million)
Table 95. Sirnaomics Recent Development
Table 96. Santaris Company Details
Table 97. Santaris Business Overview
Table 98. Santaris Revenue in Antisense and RNAi Therapeutics Business (2016-2021) & (US$ Million)
Table 99. Santaris Recent Development
Table 100. Roche Company Details
Table 101. Roche Business Overview
Table 102. Roche Antisense and RNAi Therapeutics Product
Table 103. Roche Revenue in Antisense and RNAi Therapeutics Business (2016-2021) & (US$ Million)
Table 104. Roche Recent Development
Table 105. Research Programs/Design for This Report
Table 106. Key Data Information from Secondary Sources
Table 107. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Antisense and RNAi Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. RNA Interference Features
Figure 3. Antisense RNA Features
Figure 4. Global Antisense and RNAi Therapeutics Market Share by Application: 2020 VS 2027
Figure 5. Hospital Case Studies
Figure 6. Clinic Case Studies
Figure 7. Antisense and RNAi Therapeutics Report Years Considered
Figure 8. Global Antisense and RNAi Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 9. Global Antisense and RNAi Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 10. Global Antisense and RNAi Therapeutics Market Share by Regions: 2020 VS 2027
Figure 11. Global Antisense and RNAi Therapeutics Market Share by Regions (2022-2027)
Figure 12. Global Antisense and RNAi Therapeutics Market Share by Players in 2020
Figure 13. Global Top Antisense and RNAi Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antisense and RNAi Therapeutics as of 2020
Figure 14. The Top 10 and 5 Players Market Share by Antisense and RNAi Therapeutics Revenue in 2020
Figure 15. Global Antisense and RNAi Therapeutics Revenue Market Share by Type (2016-2021)
Figure 16. Global Antisense and RNAi Therapeutics Revenue Market Share by Type (2022-2027)
Figure 17. North America Antisense and RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 18. North America Antisense and RNAi Therapeutics Market Share by Type (2016-2027)
Figure 19. North America Antisense and RNAi Therapeutics Market Share by Application (2016-2027)
Figure 20. North America Antisense and RNAi Therapeutics Market Share by Country (2016-2027)
Figure 21. United States Antisense and RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. Canada Antisense and RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Europe Antisense and RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Antisense and RNAi Therapeutics Market Share by Type (2016-2027)
Figure 25. Europe Antisense and RNAi Therapeutics Market Share by Application (2016-2027)
Figure 26. Europe Antisense and RNAi Therapeutics Market Share by Country (2016-2027)
Figure 27. Germany Antisense and RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. France Antisense and RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. U.K. Antisense and RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Italy Antisense and RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Russia Antisense and RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Nordic Antisense and RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Asia-Pacific Antisense and RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Antisense and RNAi Therapeutics Market Share by Type (2016-2027)
Figure 35. Asia-Pacific Antisense and RNAi Therapeutics Market Share by Application (2016-2027)
Figure 36. Asia-Pacific Antisense and RNAi Therapeutics Market Share by Region (2016-2027)
Figure 37. China Antisense and RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Japan Antisense and RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. South Korea Antisense and RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Southeast Asia Antisense and RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. India Antisense and RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Australia Antisense and RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Latin America Antisense and RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Antisense and RNAi Therapeutics Market Share by Type (2016-2027)
Figure 45. Latin America Antisense and RNAi Therapeutics Market Share by Application (2016-2027)
Figure 46. Latin America Antisense and RNAi Therapeutics Market Share by Country (2016-2027)
Figure 47. Mexico Antisense and RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Brazil Antisense and RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Middle East & Africa Antisense and RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Antisense and RNAi Therapeutics Market Share by Type (2016-2027)
Figure 51. Middle East & Africa Antisense and RNAi Therapeutics Market Share by Application (2016-2027)
Figure 52. Middle East & Africa Antisense and RNAi Therapeutics Market Share by Country (2016-2027)
Figure 53. Turkey Antisense and RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Saudi Arabia Antisense and RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. UAE Antisense and RNAi Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Tekmira Pharmaceuticals Revenue Growth Rate in Antisense and RNAi Therapeutics Business (2016-2021)
Figure 57. Arbutus Biopharma Revenue Growth Rate in Antisense and RNAi Therapeutics Business (2016-2021)
Figure 58. Alnylam Pharmaceuticals Revenue Growth Rate in Antisense and RNAi Therapeutics Business (2016-2021)
Figure 59. Antisense Therapeutics Revenue Growth Rate in Antisense and RNAi Therapeutics Business (2016-2021)
Figure 60. Silence Therapeutics Revenue Growth Rate in Antisense and RNAi Therapeutics Business (2016-2021)
Figure 61. Isis Pharmaceuticals Revenue Growth Rate in Antisense and RNAi Therapeutics Business (2016-2021)
Figure 62. Sirnaomics Revenue Growth Rate in Antisense and RNAi Therapeutics Business (2016-2021)
Figure 63. Santaris Revenue Growth Rate in Antisense and RNAi Therapeutics Business (2016-2021)
Figure 64. Roche Revenue Growth Rate in Antisense and RNAi Therapeutics Business (2016-2021)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed

---